SEC Comment Letter for REGENERX BIOPHARMACEUTICALS INC (RGRX) (CIK 0000707511) — Aug 19, 2021

REGENERX BIOPHARMACEUTICALS INC (RGRX) (CIK 0000707511)
Date: Aug. 19, 2021 · CIK: 0000707511 · Accession: 0000000000-21-010219

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-258873

Date

August 19, 2021

Author

Not clearly detected

Form

UPLOAD

Company

REGENERX BIOPHARMACEUTICALS INC (RGRX) (CIK 0000707511)

Letter

United States securities and exchange commission logo August 19, 2021 J.J. Finkelstein President and Chief Executive Officer REGENERX BIOPHARMACEUTICALS INC 15245 Shady Grove Road, Suite 470 Rockville, MD 20850 Re:REGENERX BIOPHARMACEUTICALS INC Registration Statement on Form S-1 Filed August 16, 2021 File No. 333-258873 Dear Mr. Finkelstein: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Margaret Schwartz at 202-551-7153 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Kimberly Lowe, Esq.

Show Raw Text

United States securities and exchange commission logo
August 19, 2021
J.J. Finkelstein
President and Chief Executive Officer
REGENERX BIOPHARMACEUTICALS INC
15245 Shady Grove Road, Suite 470
Rockville, MD 20850
Re:REGENERX BIOPHARMACEUTICALS INC
Registration Statement on Form S-1
Filed August 16, 2021
File No. 333-258873
Dear Mr. Finkelstein:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Margaret Schwartz at 202-551-7153 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Kimberly Lowe, Esq.

SecProbe.io